Today: 8 February 2026
Subscribe

Plug Power Stock Explodes 170% on Analyst Hype & Giant Hydrogen Deal

Plug Power (PLUG) Stock Skyrockets on Hydrogen Hype – Is PLUG a Buy or Bubble?

Stock Rally and Analyst Buzz PLUG’s October rally caught Wall Street’s eye. After slipping for much of 2025, the stock surged in early October as analysts turned bullish and hydrogen demand news broke. For example, H.C. Wainwright on Oct. 3 raised PLUG’s price target from $3 to $7 and maintained a Buy ratingmarketbeat.com, and HSBC upgraded Plug to a “Strong Buy” on Oct. 9marketbeat.com. These upbeat calls came as the company announced its first big electrolyzer delivery in Europe. The result: Plug’s shares nearly doubled since early September, trading around $4.05 by Oct. 14ts2.tech – near a 52-week high –
16 October 2025
NVIDIA 2025: Dominating the AI Boom – Company Overview, Key Segments, Competition, and Future Outlook

Nvidia Stock Skyrockets on $100B AI Deal – Will NVDA Hit $320 Target?

Nvidia Stock & Market Performance Nvidia’s stock is trading high in October 2025. It closed at $184.87 on Oct. 15investing.com, up slightly from the prior day, and was around $180–183 in early trading on Oct. 16reuters.com. The week of Oct. 10–16 saw some profit-taking: NVDA hit an intraday high near $195 on Oct. 10investing.com, then retreated into the low-$180s, but remains well above levels from earlier in 2025. Overall, Nvidia is up roughly 30% YTD, vastly outperforming the S&P 500ts2.tech. (For context, the 52-week range is ~$86–195reuters.com.) Trading volumes have been heavy (205–268 million shares daily recentlyinvesting.com), reflecting strong investor interest.
16 October 2025
··
Billionaire-Backed Crypto Bank Approved by Regulators – Are Tech Stocks and Crypto Ready to Soar?

Billionaire-Backed Crypto Bank Approved by Regulators – Are Tech Stocks and Crypto Ready to Soar?

OCC Approval Details The OCC’s approval letter makes Erebor the first new charter since Gould took over in June 2025benzinga.com. In announcing the decision, Gould stressed that innovative banks need not be blocked: “Permissible digital asset activities… have a place in the federal banking system if conducted in a safe and sound manner,” he saidbenzinga.com. This is a notable change of tone from prior OCC leadership. As Benzinga reports, the OCC applied its usual rigorous standards but ultimately concluded Erebor’s plan was sound, making it “the first de novo bank to receive preliminary approval under Gould’s tenure”benzinga.com. Despite the approval,
16 October 2025
··
Oracle Stock Surges on $300B AI Cloud Deal – Is a Trillion-Dollar Valuation Next?

Oracle Stock Surges on $300B AI Cloud Deal – Is a Trillion-Dollar Valuation Next?

Oracle Stock Today As of Oct. 16, Oracle (NYSE: ORCL) is trading near $304 per share. Investing.com data show ORCL closed at $303.98 on Oct. 16 (up 0.12% for the day)investing.com. This comes after a volatile week: the stock hit an all-time intraday high (~$345.69) on Sept. 10ts2.tech following the AI cloud deal announcements, then pulled back 15–20% by early October on profit-taking and margin concernsts2.techts2.tech. Overall, ORCL is up roughly 70% year-to-date, far outperforming the broader tech sector and even leaving Microsoft and Alphabet in the dustts2.tech. Even mid-month blips (like a 6% drop in early October after a
16 October 2025
···
Western Alliance Bancorp Stock Plunges on First Brands Fallout — Analysts See Upside

Western Alliance Bancorp Stock Plunges on First Brands Fallout — Analysts See Upside

Stock Trends and Recent Moves Western Alliance’s stock has been volatile recently. After rallying through summer, it tumbled in early October. On Oct 8, WAL fell about 4% amid headlines that a Jefferies-managed fund (Point Bonita) held ~$715 million in First Brands receivablests2.techmlq.ai. By Oct 15, WAL closed near $78.84, down ~4% for the dayinvesting.com. Trading volume surged as investors digested the news. A day later (Oct 16), Reuters reported WAL shares were still down ~5.4%reuters.com, despite the bank’s reassurances. Management disclosed it had filed a fraud lawsuit related to one credit and said its “criticized assets” (weak loans) actually
16 October 2025
Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

SCNX Stock Climbs on Arbli Launch Pills and a daily pill organizer: Arbli’s liquid formulation helps patients (especially children/elderly) who can’t swallow tablets. Scienture’s stock jumped sharply on Oct. 16 after the company formally launched Arbli™ in the U.S. market. In a GlobeNewswire press release that morning, Scienture announced that Arbli™ is now shipping through major pharmaceutical wholesalers nationwideglobenewswire.com. Arbli is the first FDA-approved oral liquid form of losartan, a top-selling blood pressure drug. The launch news and accompanying marketing caused traders to bid up SCNX: one trader wrote that shares moved “from yesterday’s close around 72 cents to nearly
16 October 2025
·
Virgin Galactic SPCE Stock Surges on Lawsuit Settlement and Purdue Mission News

Virgin Galactic SPCE Stock Surges on Lawsuit Settlement and Purdue Mission News

Stock Performance & Financials Virgin Galactic’s share price has been in a prolonged slump, though recent news has sparked a bounce. On Oct. 1, 2025 SPCE closed at $3.42 ts2.tech; by Oct. 16 it had rallied to about $4.89 Investing (and was up ~6.3% on the day). The stock traded in a rough range of $3.30–$3.70 through early Oct ts2.tech. Over 2025 the stock is still down roughly one-third (Benzinga reports –33% YTD Benzinga; TS2.Tech data shows ~–42% YTD through Sept ts2.tech), well underperforming the S&P500. SPCE remains extremely volatile (5‑year drawdown ~99% ts2.tech). Financially, Virgin Galactic remains pre‑revenue. Q2
16 October 2025
··
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

Strategic Samsung Partnership GRAIL’s shares surged after it announced a deal on Oct. 16 to partner with Samsung in Asia. The binding Letter of Intent involves Samsung C&T and Samsung Electronics investing $110 million in GRAIL at $70.05 per share, with Samsung C&T to distribute the Galleri multi-cancer screening test in South Koreainvesting.comprnewswire.com. This collaboration gives Samsung “a strong foothold for expanding into the cancer screening field”, according to Jaywoo Kim, EVP of Samsung C&Tprnewswire.com. GRAIL’s President of International Business, Sir Harpal Kumar, said the deal “strengthens our balance sheet and provides further cash runway” as the company advances toward test
16 October 2025
··
J.B. Hunt (JBHT) Stock Soars on Earnings Surprise – Is a Freight Sector Revival Underway?

J.B. Hunt (JBHT) Stock Soars on Earnings Surprise – Is a Freight Sector Revival Underway?

Stock Rally After Earnings Beat J.B. Hunt’s stock rallied hard on Oct. 16. Reuters reported that JBHT shares “rose nearly 16% in early trading on Thursday” (Oct 16) after the company’s cost-cutting drove a stronger-than-expected profitreuters.com. Traders noted a similar jump (about 18%) according to market news on StockTwitsstocktwits.com. The surge pushed JBHT to multi-week highs (roughly mid-$160s per share) as investors reacted to the Q3 results and upbeat comments from analysts. (For context, JBHT had closed around $138.83 on Oct. 15benzinga.com.) The broad market backdrop also helped: easing China trade worries and hopes for Fed rate cuts lifted U.S.
16 October 2025
·
Whitehawk Therapeutics Stock Rockets on AI Partnership – What Investors Need to Know

Whitehawk Therapeutics Stock Rockets on AI Partnership – What Investors Need to Know

Whitehawk’s stock popped dramatically on Oct. 16 after news of the Tempus collaboration. Shares had been around $2 per share in mid-Octoberstockinvest.us, but the new AI partnership sent them soaring in early trading. By mid-day Oct. 16, various data sites showed WHWK up roughly 50–67% on the sessioninvesting.com. (For comparison, it had already gained ~6.6% on Oct. 15stockinvest.usstocktitan.net.) The sudden jump reflects investor excitement about the Tempus deal, which was announced in a press release on Oct. 16marketscreener.com. The Tempus AI collaboration was officially billed as a “multi-year” partnership to use Tempus’s de-identified, multimodal clinical data to improve Whitehawk’s ADC
16 October 2025
Polestar Stock Skyrockets on Strong EV Sales and New Tech – What’s Next?

Polestar Stock Skyrockets on Strong EV Sales and New Tech – What’s Next?

Recent Stock Performance Polestar’s stock has been volatile in October 2025. After Q3 sales news on Oct. 9, PSNY climbed modestly (Reuters noted a ~+2% premarket risereuters.com), ending around $0.91 on Oct 15. By Oct 16 it was about $0.94investing.com. In contrast, the PSNYW warrants (which had languished at ~$0.20) saw a huge rally to ~$0.35 on Oct 16investing.com. Such warrant spikes often reflect speculative trading and have no immediate impact on company fundamentals, but they signal intense investor interest. StockAnalysis.com confirms PSNYW’s day gain of +76.6% to $0.36 on Oct 16stockanalysis.com. (PSNYW trading is thin and can move wildly.)
16 October 2025
··
United Airlines Stock Takes Off on Travel Boom and Record Revenue Forecast

United Airlines Stock Takes Off on Travel Boom and Record Revenue Forecast

Stock Performance and Recent Trends United’s stock has been climbing steadily heading into the earnings report. It closed around $104.18 on Oct. 15, up about 5% in just two days ts2.tech. This week’s rally built on a broader uptrend – shares have gained roughly 13% over the past quarter and nearly 45% year-on-year ts2.tech. Investors drove the stock higher in anticipation of strong results, aided by optimism across the airline sector. Notably, Delta’s upbeat earnings on Oct. 9 sent airline stocks higher, signaling that strength at one major carrier can lift the group ts2.tech. Market bulls argue that United’s emphasis
16 October 2025
·
Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Stock Rebounds on Moderna’s “Make-or-Break” Week Moderna’s stock is back in the spotlight after a turbulent week of news that sent the Nasdaq-listed shares swinging. On Wednesday, MRNA jumped over 5%, climbing to around $27.7 by market close marketbeat.com. The mini-rally came amid a flurry of developments – from upbeat trial data on a new cancer vaccine to analysts debating whether Moderna’s future is bright or bleak. Even after the pop, however, Moderna’s stock is a shadow of its former self: shares have cratered roughly 80% below last year’s levels marketbeat.com and are down one-third in 2025 alone. The once
16 October 2025
·
Kelly Services’ Tech-Driven Hiring Triumphs Spark Stock Rally Hopes

Kelly Services’ Tech-Driven Hiring Triumphs Spark Stock Rally Hopes

Double Honors in Staffing Leadership Kelly Services has grabbed headlines by earning dual top honors from leading industry analyst Everest Group. In the newly released 2025 U.S. Contingent Staffing PEAK Matrix assessments, Kelly was designated both a Leader and a Star Performer, recognizing its superior capabilities and momentum in supplying talent. Notably, Kelly achieved this in both the professional/administrative and industrial staffing categories, marking “the first time any firm” has ever swept both distinctions across all evaluated segments ts2.tech. This unprecedented feat underscores how far the 77-year-old staffing giant has evolved beyond traditional temp services into a tech-savvy talent solutions
16 October 2025
Theriva Biologics Stock Skyrockets 92% on Cancer Trial Breakthrough – What’s Next for TOVX?

Theriva Biologics Stock Skyrockets 92% on Cancer Trial Breakthrough – What’s Next for TOVX?

Recent Clinical Developments and Pipeline Updates Theriva Biologics – a Rockville, MD-based clinical-stage biotech – has made headlines with promising cancer trial results. On October 13, 2025, the company announced that expanded data from its VIRAGE Phase 2b trial in metastatic pancreatic ductal adenocarcinoma will be presented at the ESMO 2025 Congress on Oct. 20 ts2.tech. In this trial, patients receiving VCN-01 (an oncolytic adenovirus therapy) plus standard gemcitabine/nab-paclitaxel chemo showed markedly better outcomes than chemo alone. Interim data filed with the SEC reveal VCN-01 improved median overall survival to around 11–14 months versus ~8–11 months for chemo-only patients ts2.tech.
16 October 2025
LOBO EV Tech Rebrands & Sparks Trading Frenzy – What Investors Need to Know

LOBO EV Tech Rebrands & Sparks Trading Frenzy – What Investors Need to Know

Nasdaq Debut and Volatile Trading Lobo’s corporate makeover took effect on Oct. 16, when shareholders’ approval of a name change (dropping the “EV”) and a share reclassification became official tipranks.com. That morning, LOBO opened on Nasdaq at $0.86 and oscillated up to $0.97 before closing flat around $0.93 reuters.com. This frenetic trading came on unusually heavy volume, underscoring heightened interest around the rebrand. The Class A ordinary shares carry the same ticker “LOBO” but signal a new chapter for the company’s capital structure. Management framed the changes as a strategy to “enhance [LOBO’s] market presence” and reflect broader tech ambitions beyond just
16 October 2025
··
Marsh & McLennan’s Q3 Profit Jumps 11% Amid Rebrand to “Marsh” – What’s Next for MMC Stock?

Marsh & McLennan’s Q3 Profit Jumps 11% Amid Rebrand to “Marsh” – What’s Next for MMC Stock?

Q3 2025 Earnings: Solid Growth and an 11% Profit Jump Marsh & McLennan delivered a strong third quarter, topping expectations on both the top and bottom lines. Revenue reached $6.4 billion, up 11% from a year ago (4% on an underlying, constant-currency basis) stocktitan.net stocktitan.net. This was driven by double-digit growth in its core insurance broking unit and steady gains in consulting. The Risk & Insurance Services division (which includes its Marsh insurance brokerage and Guy Carpenter reinsurance arm) saw revenue surge +13% year-over-year to $3.9 billion stocktitan.net, boosted by firm insurance pricing earlier in the year and a rebound in client
16 October 2025
·
Axon Stock Plunges 8% Amid Market Rally – Analysts See Big Upside Ahead

Axon Stock Plunges 8% Amid Market Rally – Analysts See Big Upside Ahead

Axon Stock Sinks Despite Market Strength Axon shares suffered an unexpected jolt mid-week, falling over 8% in a single session – a steep one-day drop for a typically steady climber. The slide to $644.99 nasdaq.com on Wednesday came with no obvious bad news from the company. In fact, broader market conditions were positive: U.S. stocks rose on the same day on optimism about trade and interest rates ts2.tech. This made Axon’s decline stand out even more, as the stock vastly underperformed major indexes. Technical factors likely played a role. Axon’s plunge pushed it below its 200-day moving average (~$677) nasdaq.com,
16 October 2025
NuScale Stock Skyrockets on Historic SMR Deal – Can GE Vernova Catch Up in the Nuclear Boom?

NuScale Stock Skyrockets on Historic SMR Deal – Can GE Vernova Catch Up in the Nuclear Boom?

NuScale’s Historic SMR Deal Sparks a Nuclear Stock Rally NuScale Power’s stock is on fire after the company secured a massive 6 gigawatt SMR deployment program with the Tennessee Valley Authority (TVA) – “the largest SMR deployment in U.S. history,” according to NuScale ts2.tech. The deal, executed via NuScale’s ENTRA1 Energy venture, will see up to six 77 MWe modular reactors installed in TVA’s service area, enough to power ~4.5 million homes and dozens of data centers ts2.tech. Investors cheered the news: on October 13, SMR shares spiked ~14% intraday, and by mid-week the stock was trading around $55 – roughly 20% higher
16 October 2025
··
Duke Energy Stock Soars to Record High Amid Grid Modernization Boom – What’s Next?

Duke Energy Stock Soars to Record High Amid Grid Modernization Boom – What’s Next?

Record High on Robust Performance Duke Energy’s share price has been on a steady upswing, recently reaching a record high of $127.85 ph.investing.com. As of October 16, the stock hovers in the upper-$120s after a strong multi-week rally. It closed at $127.02 on Oct. 10 – then its highest level of 2025 ts2.tech – and pushed even higher in the following days. Year-to-date, Duke has returned roughly 15–20% ph.investing.com ts2.tech, dramatically outperforming the broader utilities sector. Over the past five years, Duke delivered about a 62% total return ts2.tech, handily beating many peer utilities and underscoring the company’s steady growth
16 October 2025
·
1 … 1,453 1,454 1,455 1,456 1,457 … 1,643

Stock Market Today

Bradesco stock price slides after earnings — what BBDC4 traders watch before Monday’s open

Bradesco stock price slides after earnings — what BBDC4 traders watch before Monday’s open

8 February 2026
Bradesco preferred shares fell 2.6% to R$20.61 Friday after the bank reported fourth-quarter net income of 6.5 billion reais and set 2026 targets for loan growth and margins. The bank guided loan book expansion of 8.5% to 10.5% and projected higher operating expenses. Investors await Brazil’s inflation data Tuesday for rate signals. Bradesco’s preferred ADR closed at $3.98 in New York.
Stellantis stock plunges: what to watch after the €22.2 billion EV reset and dividend pause

Stellantis stock plunges: what to watch after the €22.2 billion EV reset and dividend pause

8 February 2026
Stellantis shares fell 23.8% to $7.28 after the automaker flagged €22.2 billion in charges for H2 2025 and suspended its 2026 dividend. The company will sell its NextStar Energy stake and dropped battery gigafactory plans in Italy and Germany. Stellantis reported a Q4 shipment rise but warned of a net loss and negative cash flow for the second half. Investors await earnings on Feb. 26 and a strategy update in May.
Go toTop